Presence of Embolic Source and Outcome in Central Retinal Artery Occlusion.

Neurology

From the Department of Neurology (D.-W.K., K.-H.J., W.Y., Y.K., M.C., J.H., M.T.P., E.-J.L., H.-Y.J., J.-M.K., S.-B.K., S.-H.L.), Seoul National University Hospital & Seoul National University College of Medicine; Headquarters for Public Health Care (D.-W.K.), Seoul National University Bundang Hospi

Published: September 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: The etiology of central retinal artery occlusion (CRAO) is unclear in approximately 50% of patients, suggesting pathomechanical heterogeneity; moreover, little is known about outcomes according to etiology. This study investigated whether the presence of an embolic source affects outcome in CRAO.

Methods: CRAO patients within 7 days of symptom onset were retrospectively enrolled. Clinical parameters, including initial and 1-month visual acuity, CRAO subtype, and brain images, were reviewed. CRAO etiology was categorized as CRAO with or without an embolic source (CRAO-E and CRAO-E). Visual improvement was defined as a decrease in logarithm of the minimum angle of resolution ≥0.3 at 1 month.

Results: A total of 114 patients with CRAO were included. Visual improvement was noted in 40.4% of patients. Embolic sources were identified in 55.3% of patients, and visual improvement group rather than no improvement group was more commonly associated with the presence of an embolic source. In multivariable logistic regression analysis, CRAO-E independently predicted visual improvement (odds ratio 3.00, 95% CI 1.15-7.81, = 0.025).

Discussion: CRAO-E was found to be associated with a better outcome. CRAO-E may be more prone to recanalization than that CRAO-E.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558162PMC
http://dx.doi.org/10.1212/WNL.0000000000207445DOI Listing

Publication Analysis

Top Keywords

embolic source
16
visual improvement
16
presence embolic
12
source outcome
8
central retinal
8
retinal artery
8
artery occlusion
8
improvement group
8
crao
6
crao-e
6

Similar Publications

Background: Low-grade endometrial stromal sarcoma (LG-ESS) is a rare malignant tumor of the female reproductive system with atypical clinical symptoms and slow progression.

Case: A 44-year-old female with a history of intermittent severe dysmenorrhea, previous laparoscopic myomectomy, and uterine artery embolization (UAE) presented with rapidly enlarging pelvic masses. Imaging revealed uterine masses suggestive of leiomyomas, although an adnexal origin could not be excluded.

View Article and Find Full Text PDF

Cerebral infarction is a rare but serious complication after pulmonary resection for lung cancer. A 78-year-old man with hypertension and diabetes underwent video-assisted thoracoscopic right middle lobectomy for stage IA2 adenocarcinoma. On postoperative day 1, he developed acute right hemiparesis and motor aphasia.

View Article and Find Full Text PDF

Deciphering the source of an embolism is a common challenge encountered in stroke treatment. Carotid stenosis is a key source of embolic strokes. Carotid interventions can be indicated when a patient has greater than 50% stenosis in the carotid ipsilateral to the cerebral infarction, which is designated as the symptomatic carotid.

View Article and Find Full Text PDF

Objectives: Contrast extravasation on imaging studies is a clinical surrogate for bleeding severity. However, the prognostic relevance of this imaging sign needs to be evaluated. The aim of this study was to analyze the impact of contrast extravasation defined by computed tomography (CT) and angiography on massive transfusion and 30-day mortality in patients with acute bleeding undergoing transarterial embolization (TAE).

View Article and Find Full Text PDF

Background: Medicare plans employ drug utilization management strategies, including prior authorization (PA) and step therapy (ST), or formulary tier increases, to control spending. However, PA and ST can delay treatment access and encourage use of less effective/safe therapies, while formulary tier increases can lead to treatment switching/discontinuation due to higher patient out-of-pocket costs. This study modeled the impact of restricted access to direct oral anticoagulants (DOACs), and a tier increase for apixaban, on incidence and cost of clinical events in patients with non-valvular atrial fibrillation (NVAF) in the United States.

View Article and Find Full Text PDF